nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.09.2003 | Review Article

Drug Interactions of Clinical Significance for the Dermatologist

Recognition and Avoidance

verfasst von: Lori E. Shapiro, Sandra R. Knowles, Dr Neil H. Shear

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 9/2003

Einloggen, um Zugang zu erhalten

Abstract

While it would be impossible for any dermatologist to remember all potential drug interactions, knowledge of the mechanisms of drug interactions can help reduce the risk of serious adverse outcomes. Most drugs are associated with interactions but the majority do not produce significant outcomes. Dealing with drug interactions is a challenge in all clinical practice, including dermatology. New information continues to appear, and dermatologists need to know about the drugs they use.

This article focuses on the mechanisms of drug interactions. In particular, the life of a drug in terms of absorption, distribution, metabolism and excretion are reviewed with the focus on points of importance and relevance to drug interactions. The most clinically important drug interactions in dermatological practice are caused by alterations in drug metabolism. The contributions of P-glycoprotein, pharmacogenetic variation and genetic polymorphisms to drug interactions are highlighted, and the best evidence for drug interactions involving drug classes relevant to the dermatologist is presented.

Since the initial evidence for clinically relevant drug interactions comes from case reports, prescribing physicians can have a major role in collating information on interactions. By understanding the mechanisms behind drug interactions and staying alert for toxicities, we can help make drug therapy safer and reduce the fear of drug interactions.

Shapiro LE, Shear NH. Drug interactions: how scared should we be? CMAJ 1999; 161: 1266–7PubMed

Weideman RA, McKinney WP, Bernstein IH. Predictors of potential drug interactions. Hosp Pharm 1998; 33: 835–40

Jankel CA, Gitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 1993; 9: 51–9PubMedCrossRef

Schneitman-McIntire O, Farnen TA, Gordon N, et al. Medication misadventures resulting in emergency department visits at an HMO medical center. Am J Health Syst Pharm 1996; 53: 1416–22PubMed

Hamilton RA, Briceland LL, Andritz MH. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacoepidemiology 1998; 18: 1112–20

Roos TC, Merk HF. Important drug interactions in dermatology. Drugs 2000 Feb; 59 (2): 181–92

Hoey J. Drug interactions: who warns the patients [editorial]? CMAJ 1999; 161: 117

Shapiro LE, Shear NH. Drug interactions P450. Curr Probl Dermatol 2001; 13: 141–52CrossRef

du Souich P. In human therapy, is the drug-drug interaction or the adverse drug reaction the issue? Can J Clin Pharmacol 2001; 8: 153–61PubMed

10.

Andersen W, Feingold D. Adverse drug interactions clinically important for the dermatologist. Arch Dermatol 1995; 131: 468–73PubMedCrossRef

11.

Del Rosso JQ. Clinically significant drug interactions: recognition and understanding of common mechanisms. Curr Pract Med 1998; 1: 62–4

12.

Bonnabry P, Sievering J, Leemann T, et al. Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies. Clin Pharmacokinet 2001; 40 (9): 631–40PubMedCrossRef

13.

Thurmann PA, Hompesch BC. Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther 1998; 36 (11): 586–90PubMed

14.

Hoey J. Postmarketing drug surveillance: what it would take to make it work. CMAJ 2001; 165: 1293

15.

Shapiro LE, Singer MI, Shear NH. Pharmacokinetic mechanisms of drug-drug and drug-food interactions in dermatology. Curr Opin Dermatol 1997; 4: 25–31

16.

Singer MI, Shapiro LE, Shear NH. Cytochrome P450 3A: Interactions with dermatologic therapies. J Am Acad Dermatol 1997; 37: 765–71PubMedCrossRef

17.

Anastasio G, Cornell K, Menscer D. Drug interactions: keeping it straight. Am Fam Physician 1997; 56: 883–94PubMed

18.

Marchbanks C. Drug-drug interactions with fluoroquinolones. Pharmacotherapy 1993; 13: 23–5

19.

Morii M, Ueno K, Ogawa A, et al. Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharmacol Ther 2000; 68: 613–6PubMedCrossRef

20.

Bodey GP. Azole antifungal drugs. Clin Infect Dis 1992; 14: 5161–9CrossRef

21.

Zimmermann T, Yeates RA, Laufen H, et al. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994; 46: 147–50PubMedCrossRef

22.

Blum RA, D’Andrea DT, Florentino BM. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991; 114: 755–7PubMed

23.

Hansten PD. Drug interactions. Drug Interactions Newsletter 1996, 906

24.

Abramowicz M, editor. Drug interactions. Med Lett 1999; 41: 61–2

25.

Preiss R. P-glycoprotein and related transporters. Int J Clin Pharmacol Ther 1998; 36: 3–8PubMed

26.

Benet LZ, Izumi T, Zhang Y, et al. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral delivery. J Control Release 1999; 62: 25–31PubMedCrossRef

27.

Lown KS, Mao RR, Leicihtman AB, et al. Role of intestinal p-glycoprotein (mdr1) in interpatient variation in the oral bioavailabity of cyclosporine. Clin Pharmacol Ther 1997; 62: 248–60PubMedCrossRef

28.

Burkhart CN. Ivermectin: an assessment of its pharmacology, microbiology and safety. J Bet Toxicol 2000; 13: 292–6

29.

Watkins. Drug metabolism by cytochromes 450 in the liver and small bowel. Gastroenterol Clin North Am 1996; 21: 511–26

30.

Birkett DJ, Mackenzie PI, Veronese ME, et al. In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci 1993; 14: 292–4CrossRef

31.

Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes. Drug Metab Rev 1997; 29: 413–580PubMedCrossRef

32.

Ford N, Sonnichsen D. Clinically significant cytochrome P-450 drug interactions: a comment. Pharmacotherapy 1998; 18: 890–1PubMed

33.

Kolyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999; 37 (1): 8–19

34.

Michalets E. Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy 1998; 18: 84–112PubMed

35.

Park BK, Pirmohamed M, Kitteringham N. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Phamacol Ther 1995; 68: 385–424CrossRef

36.

Abramowicz M, editor. Fexofenadine. Med Lett 1996; 38: 95–6

37.

Monahan BP, Ferguson CL, Kelleavy ES, et al. Torsades do pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788–90PubMedCrossRef

38.

Honig PK, Worthan DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513–8PubMedCrossRef

39.

Cantilena LR, Sorrels S, Wiley T, et al. Fluconazole alters terfenadine pharmacokietics and electrocardiographic pharmacodynamics [abstract]. Clin Pharmacol Ther 1995; 57: 185

40.

Harris S, Hilligoss DM, Colangelo PM, et al. Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther 1995; 58 (3): 310–5PubMedCrossRef

41.

Abramowicz M, editor. Grapefruit juice interactions with drugs. Med Lett 1995; 37: 73–4

42.

Benton R, Honig P, Zamani K, et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996; 59: 383–8PubMedCrossRef

43.

Abdel-Rahman SM, Gotschall RR, Kaufmann RE, et al. Investigation of terbinafine as a CP2D6 inhibitor in vivo. Clin Pharmacol Ther 1999; 65: 465–72PubMedCrossRef

44.

Barner EL, Gray SL. Donepezil use in Alzheimer disease. Ann Pharmacother 1999; 32: 70–7

45.

Tseng CY, Wang SL, Lai MD, et al. Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1996; 60: 177–82PubMedCrossRef

46.

Kang BC, Yang CQ, Cho HK, et al. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm Drug Dispos 2002; 23 (2): 77–81PubMedCrossRef

47.

Kobayashi K, Urashima K, Shimada N, et al. Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA expressed systems of the rat. Drug Metab Dispos 2003; 31 (7): 833–6PubMedCrossRef

48.

Touchette MA, Chandrasekar PH, Milad MA, et al. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. Br J Clin Pharmacol 1992; 34: 75–8PubMedCrossRef

49.

Cadle RM, Zenon III GJ, Rodruguez-Bvarradas MC, et al. Fluconazole induced symptomatic phenytoin toxicity. Ann Pharmacother 1994; 28: 292–5

50.

Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol 1999; Suppl. 56: 26–32

51.

Ahonen J, Olkkola KT, Takala A, et al. Interaction between fluconazole and midazolam in intensive care patients. Acta Anaesthesiol Scand 1999; 43 (5): 509–14PubMedCrossRef

52.

Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 64: 332–41CrossRef

53.

Tailor S, Gupta A, Walder S, et al. Peripheral edema due to nifedipine-itraconazole interaction: a case report. Arch Dermatol 1996; 132: 350–2PubMedCrossRef

54.

Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreased the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998; 53: 445–9PubMedCrossRef

55.

Gupta AK, Katz HI, Shear NH. Drug interactions with itraconazole, fluconazole and terbinafine and their management. J Am Acad Dermatol 1999; 41: 237–48PubMedCrossRef

56.

Trujillo TC, Nolan PE. Antiarrhythmic agents: drug interactions of clinical significance. Drug Saf 2000; 23 (6): 509–32PubMedCrossRef

57.

First MR, Schroeder TJ, Michael A, et al. Cyclosporine-ketoconazole interactions: long-term follow-up and preliminary results of a randomized trial. Transplantation 1993; 55: 1000–4PubMedCrossRef

58.

Gomez D, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995; 58: 15–9PubMedCrossRef

59.

Shennib H, Auger JL. Diltiazem improves cyclosporine dosage in cystic fibrosis lung transplant recipients. J Heart Lung Transplant 1994; 10: 292–6

60.

Tatro DS, editor. Drug interaction facts (with quarterly updates). St Louis: Facts and Comparisons; 1999 Jan: xxi-xxvii, 39–40, 2406–42, 720a-b

61.

Fuhr U. Drug interactions with grapefruit juice. Drug Saf 1998; 18: 251–72PubMedCrossRef

62.

Roller L. Drugs and grapefruit juice [letter]. Clin Pharmacol Ther 1998; 1: 87CrossRef

63.

Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63: 397–402PubMedCrossRef

64.

Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral bioavailability of CYP3A4 substrates by grapefruit juice constituents: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25: 1228–33PubMed

65.

Fukuda K, Ohta T, Oshima Y, et al. Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 1997; 7: 391–6PubMedCrossRef

66.

Edwards DJ, Bellevue FH, Woster PM. Identification of 6,7-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996; 24: 1287–90PubMed

67.

Sorensen JM. Herb-drug, food-drug, nutrient-drug, and drug-drug interactions: mechanisms involved and their medical implications. J Altern Complement Med 2002; 8 (3): 293–308PubMedCrossRef

68.

Ernst E. Harmless herbs?: A review of the recent literature. Am J Med 1998; 104: 170–8PubMedCrossRef

69.

Bottorf MB. Distinct drug-interaction profiles for statins. Am J Health Syst Pharm 1999; 56: 1019–20PubMed

70.

Iliadis EA, Rosenson RS. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol 1999; 22: 25–8PubMedCrossRef

71.

McKindley D, Dufresne R. Current knowledge of the cytochrome p-450 isozyme system: can we predict clinically important drug interactions? Med Health R I 1998; 81: 38–42

72.

Hansten PD, Horn JR. Drug interactions newsletter (with quarterly updates): a clinical perspective and analysis of current developments. Vancouver: Applied Therapeutics, 1998

73.

Lode H. Evidence of different profiles of side effects and drug-drug interactions among the quinolones: the pharmacokinetic standpoint. Chemotherapy 2001; 47 Suppl. 3: 24–31; 44–8CrossRef

74.

Tatro DS, editor. Drug interaction facts (with quarterly updates). St Louis: Facts and Comparisons, 1998 Oct: 91–92, 609a-10, 685d-g, 714a-b

75.

Desta Z, Kerbusch T, Soukhova N, et al. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 1998; 285: 428–37PubMed

76.

Flockhart DA, Richard E, Woosley RL, et al. Metabolic interaction between clarithromycin and pimozide may result in cardiac toxicity [abstract]. Clin Pharmacol Ther 1996; 59: 189A

77.

Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6. Clin Pharmacol Ther 1999; 65: 10–20PubMedCrossRef

78.

Daly AK. Molecular basis of polymorphic drug metabolism. J Mol Med 1995; 73: 539–53PubMedCrossRef

79.

Wormhoudt LW, Commandeur JN, Vermeulen NP. Genetic polymorphism of human N-acetyltransferase, cytochrome P450, glutathione-s-transferase and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol 1999; 29: 59–124PubMedCrossRef

80.

Ma MK, Woo MH, McLeod HL. Genetic basis of drug metabolism. Am J Jealth syst Pharm 2002; 59 (21): 2061–9

81.

Snow J, Gibson L. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol 2995; 32: 114–6CrossRef

82.

The Medical Letter®. The Medical Letter® handbook of adverse drug interactions, 2003 edition. The Medical Letter, Inc., New Rochelle (NY), 2003

Titel: Drug Interactions of Clinical Significance for the Dermatologist
Recognition and Avoidance
verfasst von: Lori E. Shapiro
Sandra R. Knowles
Dr Neil H. Shear
Publikationsdatum: 01.09.2003
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 9/2003
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.2165/00128071-200304090-00005

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

16.04.2024 | Infektiologie | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Drug Interactions of Clinical Significance for the Dermatologist

Recognition and Avoidance

Abstract

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2003

Optimal Treatment of Pyoderma Gangrenosum

Itch Associated with Skin Disease

Antimicrobial Peptides

Cutaneous Drug Reaction Case Reports

Botulinum Toxin A

Secondary Infections in Patients with Atopic Dermatitis

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie